USPTO trademark

XUNOVLIZ

Opposition periodUSPTOWord markClass 5

"XUNOVLIZ" is a word mark owned by Novartis AG, filed at the USPTO on August 14, 2026. It is in its opposition period and covers class 5 (Pharmaceuticals).

View Novartis AG portfolioGet this data via the API
Official USPTO record
XUNOVLIZ trademark as filed
As filed with the USPTO
Status
Opposition period
Since October 6, 2026
Filed
August 14, 2026
Registered
Not yet
Expires
Not recorded
Application no.
50051551
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
1 class
Ownership

Who owns XUNOVLIZ

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Novartis AG

NOVN · Basel, Switzerland

16,867 trademarks in the portfolioView company

Representative

Maury M. Tepper, III

Tepper & Eyster, PLLC

Goods and services

What the mark covers

The products and services XUNOVLIZ is filed for, grouped by Nice class.

  • Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Official gazette publication confirmation e-mailed
  2. Published for opposition
  3. Notification of notice of publication e-mailed
  4. Approved for pub - principal register
  5. Assigned to examiner
  6. Application filing receipt mailed
  7. New application office supplied data entered
  8. New application entered
FAQ

About XUNOVLIZ

Who owns the trademark "XUNOVLIZ"?

The USPTO trademark "XUNOVLIZ" (application 50051551) is owned by Novartis AG.

What is the status of "XUNOVLIZ"?

Its status at the USPTO is: opposition period.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull XUNOVLIZ and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_01a00585-bbc7-721e-a4e1-f6ec55454f13
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_01a00585-bbc7-721e-a4e1-f6ec55454f13",
  "object": "trademark",
  "mark_text": "XUNOVLIZ",
  "status": {
    "primary": "pending",
    "stage": "pending_opposition"
  },
  "office_code": "US",
  "application_number": "50051551",
  "filing_date": "2026-08-14",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Novartis AG",
      "entity_id": "ent_019eb6f6-2c34-7440-ab0c-3adadece977e"
    }
  ]
}